Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Therapeutic Use
- Acronyms SPIRITUS
- Sponsors Aviragen Therapeutics
- 24 May 2017 Baseline characteristics presented at the 113th International Conference of the American Thoracic Society
- 13 Feb 2017 Top-line results published in an Aviragen Therapeutics media release.
- 13 Feb 2017 According to an Aviragen Therapeutics media release, this trial was conducted at approximately 68 sites in North America and Europe.